SecBot SecBot

FHTX

Foghorn Therapeutics Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001822462 Biotech & Drug Discovery
$1.79 −0.28 (−13.53%)
Nov 16 4:00 PM ET · prev $2.07
Market cap
$122.9M
Micro cap
Consensus
Buy
63% Buy or better · 16 analysts
Median target
$5.00
+179% · range $2.00–5.00
1 year
−62.8%
from $4.81 · Nov 17
30 days
−4.3%
from $1.87
52-week range
$1.79–7.07
at the low
Avg volume 20D
689.6K
shares / day
Short interest
2.25M
≈3.8% of shares · −8.3%
Days to cover
3.9
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
8
analyzed by SecBot
SecBot read BEARISH 5 reports · 90 days
Balance 1 bearish · 0 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 4/5

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q3 2026: 17 added (0 new), 6 trimmed or exited.

  • AnalystsBULLISH

    10 of 16 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest −8.3% to 2.25M shares. 3.9 days to cover, ≈3.8% of shares.

  • TrendRANGE

    34% below its 50-day average. New closing low $1.79 on Nov 16.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
JPMORGAN CHASE & CODOUBLED643,533$2.3M
Qube Research & Technologies LtdDOUBLED540,315$1.9M
PANAGORA ASSET MANAGEMENT INCADD227,091$810.7K
MORGAN STANLEYADD172,839$617.0K
UBS Group AGDOUBLED125,524$448.1K
BARCLAYS PLCADD28,766$102.7K
SIMPLEX TRADING, LLCDOUBLED15,770$56.3K
STRS OHIOADD11,700$41.8K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

16 analysts
Buy 63% rate it Buy or better
Strong Buy5Buy5Hold6Sell0Strong Sell0
12-month targets · 6 analysts

Price is below the lowest target. Median implies +179%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 2, 2026Wedbush
DOWNGRADE
DOWNGRADENeutral
Oct 2, 2026TD Cowen
DOWNGRADE
DOWNGRADEHold
Oct 2, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Oct 2, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Oct 2, 2026BTIG
DOWNGRADE
DOWNGRADENeutral

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jun 24, 2026
PARSHALL B LYNNE
Director
Jun 24, 2026
AWARD$114.2K
Jun 24, 2026
GILL SIMBA
Director
Jun 24, 2026
AWARD$114.2K
Jun 24, 2026
SMITH IAN F
Director
Jun 24, 2026
AWARD$114.2K
Jun 24, 2026
Cole Douglas G.
Director
Jun 24, 2026
AWARD$114.2K
Jun 24, 2026
Biller Scott
Director
Jun 24, 2026
AWARD$114.2K
Jun 24, 2026
Mendelsohn Michael
Director
Jun 24, 2026
AWARD$114.2K
Jun 24, 2026
Gallagher Neil
Director
Jun 24, 2026
AWARD$114.2K
Jun 24, 2026
Lynch Thomas J. Jr.
Director
Jun 24, 2026
AWARD$114.2K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q-$0.23-$0.26–-$0.18+4.2%$4.2M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
2,251,943
shares short
-8.3%
vs prior settlement
3.9
days to cover
≈3.8%
of shares outstanding
Trading halts
Oct 1, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 12, 2026 Other
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
Nov 9, 2026 SEC
Foghorn Therapeutics reported Q3 2026 net income of $58.2M, driven by a $74.1M cumulative catch-up adjustment in…
PRESS-RELEASE · Impact 4/10
Oct 5, 2026 SEC
BVF entities (Biotechnology Value Fund, BVF Partners, and affiliates) filed a Form 3 initial statement of beneficial…
3 · Impact 2/10
Sep 30, 2026 Inst.
JPMORGAN CHASE & CO · DOUBLED
643,533 shares ($2.3M)
Sep 30, 2026 Inst.
Qube Research & Technologies · DOUBLED
540,315 shares ($1.9M)
Jun 24, 2026 Insider
PARSHALL B LYNNE was granted 28,000 shares
Director @ $4.08 ($114.2K)
Jun 24, 2026 Insider
GILL SIMBA was granted 28,000 shares
Director @ $4.08 ($114.2K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent
Nov 12, 2026
Press release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. ("Foghorn" or the…
Nov 10, 2026
Earnings date
FHTX Q3 2026 Earnings Before Market Open · 2026-11-10
Nov 9, 2026
Earnings
Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update
- Advancing a novel oral small molecule in inflammatory bowel disease (IBD), with potential first-in-human trials targeted by end of 2027
Nov 5, 2026
Press release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. ("Foghorn" or the…
Oct 29, 2026
Press release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. ("Foghorn" or the…

SecBot reports

8 filings · 1 press release · 1 bullish · 1 bearish · 1 mixed · 5 neutral
All FHTX filing & press-release reports (9)